SLC17A9: A Potential Drug Target and Biomarker for Psychiatric Disorders

Target Name: SLC17A9

NCBI ID: G63910

SLC17A9

SLC17A9: A Potential Drug Target and Biomarker for Psychiatric Disorders

SLC17A9 (S17A9_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, and skeletal muscles. It is a member of the SLC family of transport proteins, which are responsible for transporting a variety of molecules across cell membranes. SLC17A9 is specifically known for its role in the transport of glutamate, a neurotransmitter that is involved in a wide range of physiological processes in the brain and body.

SLC17A9 is a potential drug target because of its involvement in neurotransmission. Many studies have shown that SLC17A9 is involved in the regulation of neurotransmitter release from axons, which are the long, thread-like structures that carry nerve signals away from the brain. This suggests that SLC17A9 could be a useful target for drugs that are designed to modulate neurotransmission. In addition, SLC17A9 is also known to be involved in the regulation of ion channels, which are responsible for controlling the flow of electrical current through cell membranes. This suggests that SLC17A9 could also be a useful target for drugs that are designed to modulate ion channels.

SLC17A9 is also a potential biomarker for a variety of neurological and psychiatric disorders. There are many studies showing that SLC17A9 is involved in the regulation of neurotransmission in the brain, and is therefore thought to be involved in the development and progression of a wide range of psychiatric disorders. and neurological disorders. For example, studies have shown that SLC17A9 is involved in the regulation of the release of dopamine, a neurotransmitter that is involved in the treatment of depression and other psychiatric disorders. In addition, SLC17A9 has also been shown to be involved in the regulation of the release of other neurotransmitters, including norepinephrine and serotonin.

SLC17A9 is also a potential target for drugs that are designed to modulate the activity of other proteins. Many studies have shown that SLC17A9 is involved in the regulation of the activity of several proteins, including the protein S100, which is known to be involved in the regulation of ion channels. This suggests that SLC17A9 could be a useful target for drugs that are designed to modulate the activity of these proteins. In addition, SLC17A9 has also been shown to be involved in the regulation of the activity of other proteins, including the protein TGIP, which is involved in the regulation of neurotransmission.

In conclusion, SLC17A9 is a protein that is expressed in various tissues of the human body, and is involved in the regulation of neurotransmission. As a result, SLC17A9 is a potential drug target and biomarker for a variety of psychiatric and neurological disorders. Future research will be important in determining the full role of SLC17A9 in neurotransmission and the development of new treatments for psychiatric and neurological disorders.

Protein Name: Solute Carrier Family 17 Member 9

Functions: Involved in vesicular storage and exocytosis of ATP. May accumulate ATP and other nucleotides in secretory vesicles such as adrenal chromaffin granules and synaptic vesicles

The "SLC17A9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC17A9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets